---
title: "Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291463103.md"
description: "Compass Therapeutics updated its corporate presentation with positive Phase 2/3 COMPANION-002 data for tovecimig in second-line biliary tract cancer, showing improved ORR and PFS. The company plans FDA engagement in Q3 2026 ahead of a BLA submission in late 2026, with potential approval in the second half of 2027."
datetime: "2026-07-01T21:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291463103.md)
  - [en](https://longbridge.com/en/news/291463103.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291463103.md)
generator: "portal-rs"
---

# Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement

**Compass updated its corporate presentation to include COMPANION-002 data showing tovecimig improved ORR and PFS in 2L biliary tract cancer and plans FDA engagement ahead of a BLA.**

**Key Highlights:**

-   COMPANION-002: Tovecimig + paclitaxel ORR 18.0% vs 5.3% for paclitaxel (BICR-assessed, p=0.0228).
-   PFS improved: median 4.7 vs 2.6 months (HR=0.44, p<0.0001) for combo vs paclitaxel.
-   OS analysis confounded by 54% control crossover; crossover subset showed median OS 12.8 vs 6.1 months (HR=0.54, p=0.04).
-   Safety profile consistent with prior data; no new safety signals reported for the combination arm.
-   Next steps: meet with FDA in Q3 2026 and plan BLA submission in late 2026 with potential approval in 2H 2027.

Original SEC Filing: Compass Therapeutics, Inc. \[ CMPX \] - 8-K - Jul. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [ENGN: Pivotal data and BLA filing for detalimogene on track, supported by strong cash reserves](https://longbridge.com/en/news/298312691.md)
- [enGene Reports Q3 2026: $266.3M Cash, $32.5M Net Loss; BLA Filing Planned 4Q26](https://longbridge.com/en/news/298313337.md)
- [Coldcard ‘Wave 3’ attacker moves Bitcoin again: ‘Moved apparently for laundering purposes’](https://longbridge.com/en/news/298228432.md)
- [Zenas Biopharma outlines obexelimab regulatory filings, pipeline milestones in corporate presentation](https://longbridge.com/en/news/298356646.md)
- [Coldcard attacker moves 45% of stolen Bitcoin through THORChain and CoinJoin, Galaxy reports](https://longbridge.com/en/news/298198144.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**